Interpace Biosciences Inc Financials
Interpace Biosciences Inc (IDXG) reported $38.7M in revenue for fiscal year 2025, down 17.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 profit was lifted by a tax benefit, while the underlying business remained cash-generative and asset-light.
In the latest year, net income of$24.6M overwhelmed operating income of$4.1M , so reported profit was driven much more by a tax benefit than by the core business. That breaks the FY2023-FY2024 pattern in which profit and cash were much closer, making earnings quality look unusually rich relative to the cash engine underneath it.
The operating model looks asset-light: free cash flow of
The balance sheet improved more through liability reduction than cash accumulation: total liabilities ended at
Financial Health Signals
Interpace Biosciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Interpace Biosciences Inc scores -4.91, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($40.2M) relative to total liabilities ($11.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Interpace Biosciences Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Interpace Biosciences Inc generates $0.24 in operating cash flow ($5.8M OCF vs $24.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Interpace Biosciences Inc generated $38.7M in revenue in fiscal year 2025. This represents a decrease of 17.5% from the prior year.
Interpace Biosciences Inc's EBITDA was $4.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 46.4% from the prior year.
Interpace Biosciences Inc reported $24.6M in net income in fiscal year 2025. This represents an increase of 267.2% from the prior year.
Interpace Biosciences Inc earned $0.89 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Interpace Biosciences Inc generated $5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.2% from the prior year.
Interpace Biosciences Inc held $2.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Interpace Biosciences Inc's gross margin was 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.
Interpace Biosciences Inc's operating margin was 10.5% in fiscal year 2025, reflecting core business profitability. This is down 6.7 percentage points from the prior year.
Interpace Biosciences Inc's net profit margin was 63.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 49.2 percentage points from the prior year.
Interpace Biosciences Inc's ROE was 110.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Interpace Biosciences Inc invested $642K in research and development in fiscal year 2025. This represents a decrease of 5.0% from the prior year.
Interpace Biosciences Inc invested $356K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.4% from the prior year.
Not reported for fiscal year 2025.
IDXG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.1M | $38.7M-17.5% | $46.9M+17.2% | $40.0M+25.7% | $31.8M-3.9% | $33.1M+2.2% | $32.4M+33.8% | $24.2M+10.6% | $21.9M+37.7% | $15.9M+21.5% | $13.1M+38.7% | $9.4M+539.9% | $1.5M-99.0% | $146.5M+15.5% | $126.9M-19.3% | $157.3M |
| Cost of Revenue | $13.1M | $14.6M-14.1% | $17.0M+13.5% | $15.0M+10.1% | $13.6M-4.9% | $14.3M-34.0% | $21.7M+36.4% | $15.9M+55.8% | $10.2M+38.6% | $7.4M+10.8% | $6.6M-3.9% | $6.9M+445.0% | $1.3M | N/A | N/A | N/A |
| Gross Profit | $23.0M | $24.1M-19.4% | $29.9M+19.4% | $25.1M+37.4% | $18.2M-3.0% | $18.8M+75.3% | $10.7M+28.7% | $8.3M-28.8% | $11.7M+37.0% | $8.5M+32.5% | $6.4M+155.5% | $2.5M+1124.3% | $206K-99.1% | $23.5M-12.5% | $26.9M-17.3% | $32.5M |
| R&D Expenses | $594K | $642K-5.0% | $676K+6.3% | $636K-9.5% | $703K-52.9% | $1.5M-46.6% | $2.8M-0.5% | $2.8M+32.3% | $2.1M+45.4% | $1.5M-11.3% | $1.6M-28.1% | $2.3M+798.8% | $255K | N/A | N/A | N/A |
| SG&A Expenses | $9.7M | $9.5M-0.1% | $9.5M+1.3% | $9.4M-14.7% | $11.0M+2.5% | $10.7M-41.2% | $18.2M+26.7% | $14.4M+65.5% | $8.7M-5.2% | $9.2M-12.9% | $10.5M-37.9% | $16.9M+18.2% | $14.3M-6.2% | $15.3M-7.0% | $16.4M-16.7% | $19.7M |
| Operating Income | $4.2M | $4.1M-49.6% | $8.1M+105.0% | $4.0M+209.4% | -$3.6M+42.9% | -$6.3M+75.7% | -$26.1M+1.4% | -$26.4M-109.3% | -$12.6M-100.7% | -$6.3M+2.3% | -$6.4M+84.1% | -$40.4M-126.7% | -$17.8M-1140.5% | -$1.4M+94.3% | -$25.2M-436.6% | -$4.7M |
| Interest Expense | N/A | N/A | N/A | -$112K+29.1% | -$158K+68.1% | -$496K-190.3% | $549K+24.8% | $440K+32.9% | $331K-23.6% | $433K-79.8% | $2.1M-42.1% | $3.7M+515.4% | $602K | $0 | N/A | N/A |
| Income Tax | N/A | -$21.2M-530350.0% | $4K-76.5% | $17K-41.4% | $29K+104.1% | -$705K-1430.2% | $53K+289.3% | -$28K-255.6% | $18K+104.6% | -$395K-143.8% | -$162K+98.8% | -$13.1M-161.2% | -$5.0M-2894.4% | $180K-13.5% | $208K+122.2% | -$939K |
| Net Income | $24.5M | $24.6M+267.2% | $6.7M+235.0% | $2.0M+109.1% | -$22.0M-46.9% | -$14.9M+43.5% | -$26.5M+1.1% | -$26.7M-110.5% | -$12.7M-201.2% | $12.6M+157.1% | -$22.0M-61.5% | -$13.6M+18.8% | -$16.8M-267.3% | -$4.6M+82.1% | -$25.5M-114.3% | -$11.9M |
| EPS (Diluted) | — | $0.89 | $0.40 | $0.45+108.7% | -$5.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.26 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IDXG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $33.8M+128.8% | $14.8M+12.8% | $13.1M-17.9% | $16.0M-58.4% | $38.4M-15.9% | $45.7M-11.4% | $51.5M+65.6% | $31.1M-15.0% | $36.6M+45.7% | $25.1M-61.2% | $64.7M-43.8% | $115.2M+66.8% | $69.1M-12.0% | $78.4M-30.8% | $113.4M |
| Current Assets | $9.9M-15.9% | $11.8M+13.0% | $10.4M-14.3% | $12.2M-0.1% | $12.2M-13.9% | $14.1M-14.5% | $16.5M-6.8% | $17.7M-10.5% | $19.8M+367.2% | $4.2M-77.9% | $19.2M-57.3% | $44.9M-28.5% | $62.7M-12.4% | $71.6M-10.9% | $80.4M |
| Cash & Equivalents | $2.5M+71.5% | $1.5M-58.2% | $3.5M-27.5% | $4.8M+80.7% | $2.7M-3.6% | $2.8M+19.4% | $2.3M-61.8% | $6.1M-60.1% | $15.2M+2424.8% | $602K-92.8% | $8.3M-64.0% | $23.1M-49.4% | $45.6M-13.5% | $52.8M-18.0% | $64.3M |
| Inventory | $1.1M-8.0% | $1.2M-1.3% | $1.2M+0.2% | $1.2M+48.4% | $825K-59.8% | $2.1M+12.4% | $1.8M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5.6M-33.9% | $8.5M+68.3% | $5.1M+0.9% | $5.0M+7.7% | $4.7M-41.8% | $8.0M-22.3% | $10.3M+9.0% | $9.5M+175.9% | $3.4M+55.6% | $2.2M-21.3% | $2.8M-26.9% | $3.8M+101.6% | $1.9M-82.2% | $10.7M+10.9% | $9.6M |
| Goodwill | N/A | N/A | N/A | N/A | $8.4M0.0% | $8.4M0.0% | $8.4M | N/A | N/A | N/A | $0-100.0% | $15.5M | $0-100.0% | $2.5M-86.7% | $18.9M |
| Total Liabilities | $11.5M-32.5% | $17.0M-75.2% | $68.7M-7.3% | $74.1M-8.4% | $80.8M+8.1% | $74.8M+33.5% | $56.0M+257.2% | $15.7M+14.2% | $13.7M-61.0% | $35.2M-35.5% | $54.7M-42.9% | $95.8M+161.8% | $36.6M-14.6% | $42.8M-20.5% | $53.9M |
| Current Liabilities | $5.1M-51.9% | $10.6M-7.2% | $11.4M-19.9% | $14.3M-8.9% | $15.7M-14.0% | $18.2M+5.4% | $17.3M+99.5% | $8.7M+7.1% | $8.1M-50.2% | $16.2M-30.5% | $23.4M-30.4% | $33.6M+6.9% | $31.4M-13.7% | $36.4M-21.0% | $46.1M |
| Long-Term Debt | N/A | N/A | N/A | $1.8M+255.4% | $520K-85.9% | $3.7M+35.5% | $2.7M | N/A | N/A | $7.9M+9.3% | $7.2M-73.4% | $27.2M | N/A | N/A | N/A |
| Total Equity | $22.4M+1108.7% | -$2.2M+96.0% | -$55.5M+4.4% | -$58.1M-36.9% | -$42.4M-45.9% | -$29.1M-549.3% | -$4.5M-129.0% | $15.4M-32.5% | $22.9M+326.4% | -$10.1M-200.4% | $10.1M-48.2% | $19.4M-40.2% | $32.5M-8.8% | $35.6M-40.1% | $59.5M |
| Retained Earnings | -$210.8M+10.4% | -$235.4M+2.8% | -$242.1M+2.8% | -$249.0M-9.7% | -$227.1M-7.0% | -$212.1M-14.2% | -$185.7M-16.8% | -$159.0M-20.6% | -$131.8M-10.2% | -$119.6M-7.5% | -$111.3M-11.4% | -$99.9M-19.2% | -$83.8M-5.8% | -$79.3M-47.5% | -$53.7M |
IDXG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.5M | $5.8M+25.5% | $4.6M+22.6% | $3.8M+149.3% | -$7.7M+11.8% | -$8.7M+37.6% | -$14.0M+26.3% | -$19.0M-118.6% | -$8.7M+43.2% | -$15.3M-100.6% | -$7.6M+61.7% | -$19.8M-21.2% | -$16.4M-366.3% | -$3.5M+65.9% | -$10.3M-618.2% | $2.0M |
| Capital Expenditures | $353K | $356K-59.4% | $876K+86.4% | $470K+46.0% | $322K-9.0% | $354K-77.5% | $1.6M+1102.3% | $131K-70.8% | $449K+1448.3% | $29K | N/A | $353K-87.6% | $2.9M+56.8% | $1.8M+63.5% | $1.1M+224.2% | $343K |
| Free Cash Flow | $4.1M | $5.5M+45.2% | $3.8M+13.6% | $3.3M+141.4% | -$8.0M+11.7% | -$9.1M+41.7% | -$15.6M+18.5% | -$19.1M-109.3% | -$9.1M+40.3% | -$15.3M | N/A | -$20.2M-5.0% | -$19.2M-260.8% | -$5.3M+53.2% | -$11.4M-794.2% | $1.6M |
| Investing Cash Flow | -$353K | -$356K+59.4% | -$876K-906.9% | -$87K-101.4% | $6.2M+2070.2% | -$315K+80.0% | -$1.6M+88.7% | -$13.9M-3006.2% | -$449K-1448.3% | -$29K | N/A | $26.4M+204.1% | -$25.4M-664.5% | -$3.3M-198.4% | -$1.1M-224.2% | -$343K |
| Financing Cash Flow | N/A | -$4.4M+23.7% | -$5.8M-15.4% | -$5.0M-267.7% | $3.0M-66.6% | $9.0M-45.9% | $16.6M-43.0% | $29.2M+324066.7% | -$9K-100.0% | $29.9M+29693.1% | -$101K+99.5% | -$21.4M-211.1% | $19.2M+6219.4% | -$314K-101.3% | -$156K-875.0% | -$16K |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $208K-8.8% | $228K-27.4% | $314K+101.3% | $156K+875.0% | $16K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IDXG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.3%-1.5pp | 63.8%+1.2pp | 62.6%+5.3pp | 57.3%+0.5pp | 56.8%+23.7pp | 33.1%-1.3pp | 34.4%-19.0pp | 53.4%-0.3pp | 53.7%+4.5pp | 49.3%+22.5pp | 26.7%+12.8pp | 14.0%-2.1pp | 16.0%-5.1pp | 21.2%+0.5pp | 20.6% |
| Operating Margin | 10.5%-6.7pp | 17.3%+7.4pp | 9.9%+21.2pp | -11.4%+7.8pp | -19.1%+61.3pp | -80.5% | -109.1% | -57.7%-18.1pp | -39.6%+9.6pp | -49.2% | -428.4% | -1209.4% | -1.0%+18.9pp | -19.9%-16.9pp | -3.0% |
| Net Margin | 63.5%+49.2pp | 14.3%+9.3pp | 5.0%+74.0pp | -69.0%-23.8pp | -45.1%+36.5pp | -81.6% | -110.4% | -58.0%-137.0pp | 79.0% | -168.2% | -144.4% | -1137.6% | -3.1%+17.0pp | -20.1%-12.6pp | -7.6% |
| Return on Equity | 110.0% | N/A | N/A | N/A | N/A | N/A | N/A | -82.2%-137.1pp | 54.8% | N/A | -135.3%-49.0pp | -86.3%-72.2pp | -14.1%+57.6pp | -71.6%-51.6pp | -20.0% |
| Return on Assets | 72.7%+27.4pp | 45.3%+30.0pp | 15.3%+152.7pp | -137.4%-98.5pp | -38.9%+19.0pp | -57.9%-6.0pp | -51.9%-11.1pp | -40.8%-75.1pp | 34.3%+121.8pp | -87.5%-66.5pp | -21.0%-6.5pp | -14.5%-7.9pp | -6.6%+25.9pp | -32.5%-22.0pp | -10.5% |
| Current Ratio | 1.94+0.8x | 1.11+0.2x | 0.91+0.1x | 0.85+0.1x | 0.780.0x | 0.77-0.2x | 0.95-1.1x | 2.04-0.4x | 2.45+2.2x | 0.26-0.6x | 0.82-0.5x | 1.34-0.7x | 2.000.0x | 1.97+0.2x | 1.74 |
| Debt-to-Equity | 0.51 | N/A | N/A | N/A | N/A | N/A | N/A | 1.02+0.4x | 0.60 | N/A | 0.72-0.7x | 1.40+0.3x | 1.13-0.1x | 1.20+0.3x | 0.90 |
| FCF Margin | 14.1%+6.1pp | 8.0%-0.3pp | 8.3%+33.5pp | -25.2%+2.2pp | -27.4%+20.6pp | -48.0%+30.8pp | -78.8%-37.1pp | -41.7%+54.5pp | -96.2% | N/A | -214.1% | -1304.5% | -3.6%+5.3pp | -9.0%-10.0pp | 1.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Interpace Biosciences Inc Ranks
Frequently Asked Questions
What is Interpace Biosciences Inc's annual revenue?
Interpace Biosciences Inc (IDXG) reported $38.7M in total revenue for fiscal year 2025. This represents a -17.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Interpace Biosciences Inc's revenue growing?
Interpace Biosciences Inc (IDXG) revenue declined by 17.5% year-over-year, from $46.9M to $38.7M in fiscal year 2025.
Is Interpace Biosciences Inc profitable?
Yes, Interpace Biosciences Inc (IDXG) reported a net income of $24.6M in fiscal year 2025, with a net profit margin of 63.5%.
What is Interpace Biosciences Inc's EBITDA?
Interpace Biosciences Inc (IDXG) had EBITDA of $4.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Interpace Biosciences Inc's gross margin?
Interpace Biosciences Inc (IDXG) had a gross margin of 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Interpace Biosciences Inc's operating margin?
Interpace Biosciences Inc (IDXG) had an operating margin of 10.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Interpace Biosciences Inc's net profit margin?
Interpace Biosciences Inc (IDXG) had a net profit margin of 63.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Interpace Biosciences Inc's return on equity (ROE)?
Interpace Biosciences Inc (IDXG) has a return on equity of 110.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Interpace Biosciences Inc's free cash flow?
Interpace Biosciences Inc (IDXG) generated $5.5M in free cash flow during fiscal year 2025. This represents a 45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Interpace Biosciences Inc's operating cash flow?
Interpace Biosciences Inc (IDXG) generated $5.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Interpace Biosciences Inc's total assets?
Interpace Biosciences Inc (IDXG) had $33.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Interpace Biosciences Inc's capital expenditures?
Interpace Biosciences Inc (IDXG) invested $356K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Interpace Biosciences Inc spend on research and development?
Interpace Biosciences Inc (IDXG) invested $642K in research and development during fiscal year 2025.
What is Interpace Biosciences Inc's current ratio?
Interpace Biosciences Inc (IDXG) had a current ratio of 1.94 as of fiscal year 2025, which is generally considered healthy.
What is Interpace Biosciences Inc's debt-to-equity ratio?
Interpace Biosciences Inc (IDXG) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Interpace Biosciences Inc's return on assets (ROA)?
Interpace Biosciences Inc (IDXG) had a return on assets of 72.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Interpace Biosciences Inc's Altman Z-Score?
Interpace Biosciences Inc (IDXG) has an Altman Z-Score of -4.91, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Interpace Biosciences Inc's Piotroski F-Score?
Interpace Biosciences Inc (IDXG) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Interpace Biosciences Inc's earnings high quality?
Interpace Biosciences Inc (IDXG) has an earnings quality ratio of 0.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.